Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Lotus Pharmaceutical Co's Revenue for the
three
months ended in Mar. 2026 was NT$8,644 Mil. Lotus Pharmaceutical Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$7,435 Mil.
Hence, Lotus Pharmaceutical Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.16.
Lotus Pharmaceutical Co (TPE:1795) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Lotus Pharmaceutical Co Receivables Turnover Related Terms
Lotus Pharmaceutical Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Lotus Pharmaceutical Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co Receivables Turnover Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co (TPE:1795) has a Receivables Turnover of 1.16 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lotus Pharmaceutical Co and its competitors. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #766 out of 950 companies in the Drug Manufacturers industry, placing it in the top 80.6%.
Is Lotus Pharmaceutical Co's Receivables Turnover too high?
Lotus Pharmaceutical Co's current Receivables Turnover is 1.16. The Drug Manufacturers industry median Receivables Turnover is 5.07. Lotus Pharmaceutical Co's value of 1.16 is 77.1% below this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #766 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lotus Pharmaceutical Co has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #766 out of 950 companies for Receivables Turnover. This places Lotus Pharmaceutical Co in the lower half of its industry. The industry median Receivables Turnover is 5.07. Lotus Pharmaceutical Co's value of 1.16 is 77.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current Receivables Turnover of 1.16 is 77.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current Receivables Turnover is 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$447.53, compared to a current price of NT$173.00 — trading 61.3% below its estimated fair value. The current Receivables Turnover is 1.16 and 77.1% below the Drug Manufacturers industry median of 5.07. Lotus Pharmaceutical Co's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current Receivables Turnover is 1.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$173.00 is trading 61.3% below its estimated GF Value™ of NT$447.53.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
Receivables Turnover: 1.16
GF Value™: NT$447.53 vs. price of NT$173.00 (61.3% below fair value)
Industry Position: 77.1% below the Drug Manufacturers median (#766 of 950)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
78GF Score
Get the complete analysis for TPE:1795
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
